电子邮件 | ema***@***.com | 获取Email |
---|
电子邮件 | ema***@***.com | 获取Email |
---|
Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. Biotie is a part of Acorda Therapeutics Inc. Group ("Acorda") and its shares, excluding of those owned by Acorda, are currently subject to a redemption process in accordance with the Finnish Companies Act.
公司 | Biotie Therapies |
---|---|
职位 | VP Project and Portfolio Management |
地点 | United States |
部门 | |
头衔 | VP Project and Portfolio Management at Biotie Therapies Inc. |
Kathleen M 在 Biotie Therapies 担任 VP Project and Portfolio Management at Biotie Therapies Inc.
Kathleen M 在 Biotie Therapies 的职位是 VP Project and Portfolio Management at Biotie Therapies Inc.
Kathleen M 的电子邮件地址是 ema***@***.com
Kathleen M 的电话号码是 -
Kathleen M 的公司电话号码是 +358****
Kathleen M 在 pharmaceuticals 工作。
Kathleen M 的一些同事包括Leena LeenaKathleen M、。
Kathleen M联系方式: 电子邮件地址:ema***@***.com 电话号码:-
Kathleen M 的个人领英是:
Kathleen M 的办公地点:Joukahaisenkatu 6, Turku, Other, FI, FI-20520
Top-ranked on G2 Crowd
全球B2B企业库 海关贸易数据 展会采购数据
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd